Drug Discovery & DDS– category –
-
FDA Approves Vertex’s Zanvastro: First Disease-Modifying ASO Therapy for Alexander Disease
Healio USA Overview The U.S. FDA has approved Zanvastro (zilgannersen), an antisense oligonucleotide (ASO) therapy from Vertex Pharmaceuticals, for pediatric and adult patients with Alexander disease. This marks the first disease-modifyi... -
Oral GLP-1 Receptor Agonists Foundayo (Orforglipron) and Wegovy Pill (Oral Semaglutide) Demonstrate Average Weight Loss of 12.4% and 16.6% Respectively by 2026
PrivateDoc® Unknown Overview By 2026, two oral GLP-1 receptor agonists, Foundayo (orforglipron) and Wegovy pill (oral semaglutide), are approved for weight management in the UK. Foundayo, a small-molecule non-peptide, can be taken with o... -
Novel Bispecific Antibodies Pumitamig, PF-08634404, and INCA033890-303 Advance to Phase 3 in Colorectal Cancer Trials
Fight Colorectal Cancer USA Overview The September 2026 Colorectal Cancer (CRC) clinical trial roundup highlights several promising Phase 3 studies featuring novel bispecific antibodies. These include pumitamig (targeting PD-L1 and VEGF-... -
Google DeepMind’s AlphaFold 3 Achieves Unprecedented Accuracy in Predicting Molecular Interactions, Driving AI-Discovered Drugs to Phase III Trials
New Market Pitch Unknown Overview AI drug discovery is now fully functional in structural prediction, molecular design, lead optimization, and protein engineering. Google DeepMind and Isomorphic Labs' AlphaFold 3 demonstrates superior ac... -
Eli Lilly’s Foundayo® (Orforglipron) Receives FDA Approval as First Oral Non-Peptide GLP-1 Receptor Agonist, Demonstrates Significant Weight Loss and Cardiometabolic Improvement
Obesity Medicine Review Unknown Overview Eli Lilly's Orforglipron, branded as Foundayo®, has received FDA approval as the latest oral GLP-1 receptor agonist. Distinguishing itself from oral semaglutide (Wegovy®) as a small-molecule, non-... -
Ivonescimab Significantly Improves Overall Survival vs. Pembrolizumab in First-Line PD-L1 Positive Advanced NSCLC
The ASCO Post Unknown Overview Ivonescimab, a first-in-class PD-1/VEGF bispecific antibody, demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to pembrolizumab as a first-line... -
BioNTech Announces gotistobart Phase III Achieves Median OS of 18.5 Months in Squamous NSCLC at WCLC 2026
european biotechnology Germany Overview At the World Conference on Lung Cancer (WCLC) 2026 in Seoul, BioNTech presented pivotal data from the Phase III PRESERVE-003 trial for gotistobart (BNT316/ONC-392), a pH-sensitive anti-CTLA-4 antib... -
Novel Bispecific ADC ICP-B381, Targeting PSMA and STEAP1, Approved for Phase 1 Clinical Trials in China for Prostate Cancer; US IND Submission Underway
Prostate Warriors China Overview ICP-B381, a novel bispecific antibody-drug conjugate (ADC) designed to simultaneously target PSMA and STEAP1, has received approval from Chinese regulatory authorities to commence Phase 1 clinical trials ... -
Gan & Lee Pharmaceuticals Initiates Phase I Trial for Once-Weekly Oral GLP-1 Peptide GZC8072 in China, Targeting Obesity and Type 2 Diabetes
AllSci China Overview Gan & Lee Pharmaceuticals Co., Ltd. has commenced its Phase I clinical trial for GZC8072, a novel once-weekly oral GLP-1 receptor peptide agonist, targeting type 2 diabetes and weight management in overweight or... -
Drug Discovery & DDS Weekly Report September 13, 2026
▼ ▼ ▼ If the infographic makes you want to read the full report, please click the download button below. ▼ ▼ ▼ 📄 Weekly Report September 13, 2026 (PDF) — Download Weekly Report September 13, 2026 (PDF) — DownloadDownload 🎙 Podcast Septe...
